Itolizumab, an anti-CD6 mAb that targets the CD6/CD166 axis, inhibited CD4 and CD8 T-cell activation and proliferation in pre-GvHD samples, but inhibition was less prominent in samples collected after aGvHD onset. The gene discussed is CD6; the disease is graft versus host disease.